Clinical Trial Update: CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating CAR-T therapy after autologous stem cell transplant for relapsed/refractory B-cell non-Hodgkin lymphoma with high-risk featu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CAR-T therapy following autologous stem cell transplant (Chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: Ruijin Hospital | Conditions: B-cell Non Hodgkin Lymphoma | Phase 2 | Status: RECRUITING